{
  "docId": "019de070-f25b-768c-8e97-0a8e2cca01a8",
  "docSlug": "33fe21e9496eb3ab78f47a4da9fb6e50",
  "documentTitle": "AbCellera | Results Presentation Deck | 15 slides",
  "authorId": "abcellera",
  "authorName": "AbCellera",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.5458937,
  "pageNumber": 7,
  "pageCount": 15,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "Q1 2021 Business Update slide.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-f25b-768c-8e97-0a8e2cca01a8/7",
  "deckHref": "/decks/019de070-f25b-768c-8e97-0a8e2cca01a8",
  "deckJsonHref": "/decks/019de070-f25b-768c-8e97-0a8e2cca01a8.json",
  "deckAnchorHref": "/decks/019de070-f25b-768c-8e97-0a8e2cca01a8#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.65,
        "y": 0.65
      },
      "kind": "callout",
      "text": "Lilly recently transitioned to the combination of bamlanivimab and etesevimab in the US.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "af2d04a2-b663-4479-b436-c597d6a382c7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.07,
        "y": 0.63
      },
      "kind": "list",
      "text": "400K+ patients treated\n20K+ patients kept out of hospital\n11K+ lives saved",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "88936908-b8e7-4e26-a2db-60232a3d3f97",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.07,
        "y": 0.47
      },
      "kind": "paragraph",
      "text": "Since being authorized for emergency use by the US FDA in November 2020, bamlanivimab has prevented hospitalizations and death:",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "af6b8ecd-6d49-4eab-9d4e-13f9d3741b76",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.07,
        "y": 0.8
      },
      "kind": "paragraph",
      "text": "To address emerging variants, bamlanivimab has been evaluated in clinical trials with two other antibodies, including etesevimab and VIR-7831.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d40290cc-1cc9-465a-86c4-5f3df14c7f33",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Q1 2021 BUSINESS UPDATE. COVID-19 PROGRAM",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "536dc541-570a-4213-84cd-09e8b50e968a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.7,
        "x": 0.05,
        "y": 0.11
      },
      "kind": "title",
      "text": "BAMLANIVIMAB: THE MOST BROADLY USED COVID-19 ANTIBODY IN THE WORLD",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "81186b5f-0e75-40e1-8d4a-0d7c62f03a07",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "AIDA Model",
      "slug": "aida-model",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "c62dc393-ec0a-4a47-bc58-a8441f21b021",
      "evidence": "The slide presents key takeaways and a call to action, following the AIDA model (Attention, Interest, Desire, Action)",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 13,
      "from": 5,
      "beatId": "50788a00-2f28-4677-a130-9d230f0e6bf2",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The key takeaways, financials, and KPI overview slides demonstrate progress",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 13,
      "from": 4,
      "name": "Logic Chain",
      "slug": "01-logic-chain",
      "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis",
      "matchId": "b7044550-102b-4996-80c0-09e45d91d19f",
      "evidence": "The key messages and KPI overview slides form a logical chain",
      "position": 0,
      "objective": "To demonstrate the logic behind AbCellera's growth strategies",
      "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)",
      "confidence": 0.7,
      "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion"
    },
    {
      "to": 13,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "d713c92c-bf37-40bc-aa90-f08f6d0fe780",
      "evidence": "The financial performance and partnership growth slides imply the costs of inaction",
      "position": 1,
      "objective": "To highlight the consequences of not investing in COVID-19 programs",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}